Scott Applebaum
Chief Legal & Corporate Development OfficerMr. Scott Applebaum is Chief Legal & Corporate Development Officer of Windward Bio AG and Windward Bio Group AG from January 2025. Mr. Applebaum served as an Independent Director at Cingulate Inc. since August 2022 until December 06, 2023. He joined the Cingulate Inc. in August 2022. He servds as Chief Legal Officer & Corporate Secretary at VectivBio Holding AG since August 2021. Mr. Applebaum served as Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs at Trevena, Inc. since February 10. 2020 until August 31, 2021 and served as Corporate Secretary until August 31, 2021. Mr. Applebaum was President of Context Therapeutics. He served as General Counsel and Corporate Secretary of Vitae Pharmaceuticals, Inc. from August 10, 2016 to October 25, 2016 and where he played a key role in the sale of Vitae to Allergan plc. Mr. Applebaum served as the Chief Legal Officer of Medgenics, Inc. from September 8, 2014 to September 2016 and served as its Corporate secretary until September 2016. Mr. Applebaum has legal and regulatory experience gleaned from global leadership roles at small and large pharmaceutical companies, including Shire in multiple regulatory affairs, corporate compliance and legal positions, from heading its Specialty Pharma Legal department, to heading its Global Regulatory Affairs department and finally overseeing its Neuroscience Business Unit. Throughout his tenure at Shire, Mr. Applebaum provided counsel to its executive leadership team on key corporate and regulatory compliance matters, in addition to supporting its various acquisitions. Mr. Applebaum spent few years at Shire Pharmaceuticals, as Senior Vice President of the Global Neuroscience Business Unit based in Nyon, Switzerland. He initially joined Shire in 2004 as Senior Vice President and Associate General Counsel. He served as Senior Vice President of Legal, Senior Vice President of Global Regulatory Affairs and Quality Assurance He then transitioned to Regulatory Affairs, with overall responsibility for the regulatory strategy, execution, operations and compliance for Shire Specialty Pharmaceutical products worldwide. He began his pharmaceutical career at Bristol-Myers Squibb, where he served as Senior Counsel of the U.S. Medicines and Medical Imaging business unit. Mr. Applebaum earned his J.D. from Stanford University Law School, where he was a member of the Stanford Law Review. He graduated summa cum laude from The Wharton School of the University of Pennsylvania with a B.S. in economics with a concentration in accounting and finance.
Positions
- Company NameWindward Bio Group AGStock CodeWWBPositionChief Legal & Corporate Development OfficerColleagues
- LSLuca SantarelliCEO & Chair of the Board of Directors
- CDClaudia D'AugustaChief Financial Officer
- KAKevin Andrew HarrisChief Operating Officer
- NKNoel KurdiSenior Vice President of Investor Relations & Communications
- SSSandip S. KapadiaLead Independent Director
- DBDavid BonitaIndependent Director
- OSOtello StampacchiaIndependent Director
- IRIqbal Rasool MuftiIndependent Director
